| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT05254743 A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic… |
Enrollment increased: 662 -> 737 participants |
| 2026-06-10 | NCT05254743 A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic… |
date change Primary completion pushed: 2025-06-10 -> 2027-10 |
| 2026-05-28 | NCT06973187 A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in… |
Trial sites expanded: 149 -> 154 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-03 | NCT07622784 Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma | Phase 2 | Not Yet Recruiting |
| 2026-06-03 | NCT07624799 Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06876649 | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic… | Chronic Lymphocytic Leukemia | Recruiting |
| Phase 3 | |||
| NCT07342478 | ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R… | CLL / SLL | Recruiting |
| NCT06973187 | A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05254743 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05023980 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT07516093 | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL | B-cell Lymphoma | Not Yet Recruiting |
| NCT04666038 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With… | Lymphoma, Mantle-Cell | Active, Not Recruiting |
| NCT07220187 | Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter… | Richter Syndrome | Not Yet Recruiting |
| Phase 2 | |||
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06333262 | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06466122 | Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06553872 | Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R… | Mantle Cell Lymphoma | Recruiting |
| NCT06252675 | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | Mantle Cell Lymphoma | Recruiting |
| NCT06263491 | Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and… | Mantle Cell Lymphoma | Recruiting |
| NCT05536349 | Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for… | Leukemia | Recruiting |
| NCT05529069 | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell… | Mantle Cell Lymphoma | Recruiting |
| NCT06588478 | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT07231952 | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's… | Waldenstrom Macroglobulinemia | Recruiting |
| NCT06948786 | Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A… | Grade 1 Follicular Lymphoma | Recruiting |
| NCT05677919 | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT06522386 | GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax… | Mantle Cell Lymphoma | Active, Not Recruiting |